EUVIMEDEUVIMED entdecken
Open Access

Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia

Christina Glytsou iD, Xufeng Chen iD, Emmanouil Zacharioudakis iD, Wafa Al-Santli iD, Hua Zhou iD, Bettina Nadorp iD, Soobeom Lee iD, Audrey Lasry iD, Zhengxi Sun iD, Dimitrios Papaioannou iD, Michael Cammer iD, Kun Wang iD und 9 weitere

Cancer Discovery · 07.07.2023 · 13 (7) · 1656-1677

DOI: 10.1158/2159-8290.cd-22-0601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Discovery, online erschienen am 24.04.2023. Verfasst von Christina Glytsou und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, NYU Grossman School of Medicine, New York, New York. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Antineoplastic Agents. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCRR NIH HHS, NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BH3 mimetics are used as an efficient strategy to induce cell death in several blood malignancies, including acute myeloid leukemia (AML). Venetoclax, a potent BCL-2 antagonist, is used clinically in combination with hypomethylating agents for the treatment of AML. Moreover, MCL1 or dual BCL-2/BCL-xL antagonists are under investigation. Yet, resistance to single or combinatorial BH3-mimetic therapies eventually ensues. Integration of multiple genome-wide CRISPR/Cas9 screens revealed that loss of mitophagy modulators sensitizes AML cells to various BH3 mimetics targeting different BCL-2 family members. One such regulator is MFN2, whose protein levels positively correlate with drug resistance in patients with AML. MFN2 overexpression is sufficient to drive resistance to BH3 mimetics in AML. Insensitivity to BH3 mimetics is accompanied by enhanced mitochondria–endoplasmic reticulum interactions and augmented mitophagy flux, which acts as a prosurvival mechanism to eliminate mitochondrial damage. Genetic or pharmacologic MFN2 targeting synergizes with BH3 mimetics by impairing mitochondrial clearance and enhancing apoptosis in AML. Significance: AML remains one of the most difficult-to-treat blood cancers. BH3 mimetics represent a promising therapeutic approach to eliminate AML blasts by activating the apoptotic pathway. Enhanced mitochondrial clearance drives resistance to BH3 mimetics and predicts poor prognosis. Reverting excessive mitophagy can halt BH3-mimetic resistance in AML. This article is highlighted in the In This Issue feature, p. 1501

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteAntineoplastic AgentsHumansMyeloid Cell Leukemia Sequence 1 ProteinMitophagyApoptosisCell DeathProto-Oncogene Proteins c-bcl-2Cell Line, Tumor

Substanzen

Myeloid Cell Leukemia Sequence 1 ProteinProto-Oncogene Proteins c-bcl-2Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, NYU Grossman School of Medicine, New York, New York.
  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Health and NYU Grossman School of Medicine, New York, New York.
  • Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey.
  • Department of Pediatrics, Robert Wood Johnson Medical School, and Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey.
  • Department of Biochemistry, Albert Einstein College of Medicine, Bronx, New York.
  • Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.

ORCID-Profile: Christina Glytsou, Xufeng Chen, Emmanouil Zacharioudakis, Wafa Al-Santli, Hua Zhou, Bettina Nadorp, Soobeom Lee, Audrey Lasry, Zhengxi Sun, Dimitrios Papaioannou, Michael Cammer, Kun Wang, Tomasz Zal, Malgorzata Anna Zal, Bing Z Carter, Jo Ishizawa, Raoul Tibes, Aristotelis Tsirigos, Michael Andreeff, Evripidis Gavathiotis, Iannis Aifantis

Förderung

  • NCI NIH HHS
  • NCRR NIH HHS
  • NIA NIH HHS
  • National Cancer Institute
  • Leukemia and Lymphoma Society

Zitieren

APA

Glytsou, C., Chen, X., Zacharioudakis, E., Al-Santli, W., Zhou, H., Nadorp, B., Lee, S., Lasry, A., Sun, Z., Papaioannou, D., Cammer, M., Wang, K., Zal, T., Zal, M. A., Carter, B. Z., Ishizawa, J., Tibes, R., Tsirigos, A., Andreeff, M., …, & Aifantis, I. (2023). Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discovery, 13(7), 1656-1677. https://doi.org/10.1158/2159-8290.cd-22-0601

Vancouver

Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, et al. Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Discovery. 2023;13(7):1656-1677. doi:10.1158/2159-8290.cd-22-0601

BibTeX
@article{Glytsou2023,
  author = {Glytsou, Christina and Chen, Xufeng and Zacharioudakis, Emmanouil and Al-Santli, Wafa and Zhou, Hua and Nadorp, Bettina and Lee, Soobeom and Lasry, Audrey and Sun, Zhengxi and Papaioannou, Dimitrios and Cammer, Michael and Wang, Kun and Zal, Tomasz and Zal, Malgorzata Anna and Carter, Bing Z and Ishizawa, Jo and Tibes, Raoul and Tsirigos, Aristotelis and Andreeff, Michael and Gavathiotis, Evripidis and Aifantis, Iannis},
  title = {Mitophagy Promotes Resistance to BH3 Mimetics in Acute Myeloid Leukemia},
  journal = {Cancer Discovery},
  year = {2023},
  volume = {13},
  number = {7},
  pages = {1656--1677},
  doi = {10.1158/2159-8290.cd-22-0601}
}
Kostenlos starten →